Compare BEEP & LONA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BEEP | LONA |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United States | United States |
| Employees | N/A | 19 |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.3M | 81.5M |
| IPO Year | 2021 | N/A |
| Metric | BEEP | LONA |
|---|---|---|
| Price | $2.00 | $7.48 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.50 | ★ $10.00 |
| AVG Volume (30 Days) | 28.3K | ★ 29.4K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,075,000.00 | N/A |
| Revenue This Year | $5.77 | N/A |
| Revenue Next Year | $22.12 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.29 | $4.21 |
| 52 Week High | $4.07 | $14.21 |
| Indicator | BEEP | LONA |
|---|---|---|
| Relative Strength Index (RSI) | 62.54 | 46.62 |
| Support Level | $1.79 | $6.86 |
| Resistance Level | $2.25 | $9.78 |
| Average True Range (ATR) | 0.17 | 0.46 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 70.18 | 73.44 |
Mobile Infrastructure Corp focus on acquiring, owning and optimizing parking facilities and related infrastructure, including parking lots, parking garages, and other parking structures throughout the United States. It operates in a single reportable segment: parking. The parking segment derives revenue from managed property revenue and rental income at parking facilities. The company provides access to property and space for the parker's vehicle and charges fees that vary based on the level of usage. The company derives all of its revenue domestically.
LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.